CA2229405C - Methods for enhancing the production of interferon in cell culture - Google Patents
Methods for enhancing the production of interferon in cell culture Download PDFInfo
- Publication number
- CA2229405C CA2229405C CA002229405A CA2229405A CA2229405C CA 2229405 C CA2229405 C CA 2229405C CA 002229405 A CA002229405 A CA 002229405A CA 2229405 A CA2229405 A CA 2229405A CA 2229405 C CA2229405 C CA 2229405C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- interferon
- pkr
- poly
- progeny
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 98
- 102000014150 Interferons Human genes 0.000 title claims abstract description 94
- 229940079322 interferon Drugs 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 27
- 238000004113 cell culture Methods 0.000 title abstract description 27
- 230000002708 enhancing effect Effects 0.000 title abstract description 8
- 239000000411 inducer Substances 0.000 claims abstract description 40
- 229940047124 interferons Drugs 0.000 claims abstract description 23
- 230000016396 cytokine production Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 124
- 108010037623 eIF-2 Kinase Proteins 0.000 claims description 74
- 102000010982 eIF-2 Kinase Human genes 0.000 claims description 64
- 230000014509 gene expression Effects 0.000 claims description 17
- 230000037452 priming Effects 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 14
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 6
- 241000606161 Chlamydia Species 0.000 claims description 6
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 241000606701 Rickettsia Species 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 239000003226 mitogen Substances 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 102000003792 Metallothionein Human genes 0.000 claims description 4
- 108090000157 Metallothionein Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 2
- 239000003710 calcium ionophore Substances 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 abstract description 19
- 241000700605 Viruses Species 0.000 abstract description 15
- 210000004102 animal cell Anatomy 0.000 abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 8
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 5
- 102000020233 phosphotransferase Human genes 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000012261 overproduction Methods 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 241000710188 Encephalomyocarditis virus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241001529936 Murinae Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002799 interferon inducing agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000008014 Eukaryotic Initiation Factor-2 Human genes 0.000 description 2
- 108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 2
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 102000001617 Interferon Receptors Human genes 0.000 description 2
- 108010054267 Interferon Receptors Proteins 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000044003 human EIF2AK2 Human genes 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003682 vanadium compounds Chemical class 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US262195P | 1995-08-22 | 1995-08-22 | |
| US60/002,621 | 1995-08-22 | ||
| PCT/US1996/013627 WO1997008324A1 (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2229405A1 CA2229405A1 (en) | 1997-03-06 |
| CA2229405C true CA2229405C (en) | 2004-03-02 |
Family
ID=21701659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002229405A Expired - Fee Related CA2229405C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
| CA2229163A Expired - Lifetime CA2229163C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2229163A Expired - Lifetime CA2229163C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US5840565A (enExample) |
| EP (2) | EP0846160B1 (enExample) |
| JP (2) | JP4267693B2 (enExample) |
| CN (1) | CN1161469C (enExample) |
| AT (1) | ATE289348T1 (enExample) |
| AU (2) | AU6857696A (enExample) |
| BR (1) | BR9610550A (enExample) |
| CA (2) | CA2229405C (enExample) |
| DE (1) | DE69634360T2 (enExample) |
| WO (2) | WO1997008324A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855519B2 (en) * | 1995-08-22 | 2005-02-15 | The Regents Of The University Of California | Methods for enhancing the production of interferon in cell culture |
| US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| US6740519B1 (en) * | 1997-11-03 | 2004-05-25 | Mount Sinai School Of Medicine | Immortalized, homozygous stat1-deficient mammalian cell lines and their uses |
| SK288544B6 (sk) * | 1998-06-12 | 2018-03-05 | Mount Sinai School Of Medicine | Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie |
| US6762038B1 (en) * | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
| CN1399681A (zh) * | 1999-06-15 | 2003-02-26 | 基因特罗生物治疗公司 | 在细胞培养物中增强细胞因子产生的方法 |
| EP1067179A1 (en) * | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
| US20010031859A1 (en) * | 1999-09-08 | 2001-10-18 | Lau Allan S. | High level cytokine production with enhanced cell viability |
| HK1048135A1 (zh) * | 1999-09-08 | 2003-03-21 | Genetrol Biotherapeutics | 具增强细胞活力功能的高产量的细胞变动素(cytokine) |
| WO2001077394A1 (en) | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
| IL136232A0 (en) * | 2000-05-18 | 2001-05-20 | Bar Ilan University Res Author | Measurements of enzymatic activity in a single, individual cell in population |
| ATE318893T1 (de) * | 2000-08-04 | 2006-03-15 | Chiron Corp | Verbesserte replikation von hcv rna |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US6864061B2 (en) | 2000-09-14 | 2005-03-08 | Genetrol Biotherapeutics, Inc. | Method for screening compounds for anti-inflammatory activity |
| WO2002062837A2 (en) * | 2000-12-19 | 2002-08-15 | Genetrol Biotherapeutics, Inc. | Cells with enhanced pkr expression for increasing cytokine production |
| DE10104094C1 (de) * | 2001-01-31 | 2002-07-25 | Angelika Vallbracht-Flehmig | Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung |
| EP1438385A1 (en) * | 2001-10-25 | 2004-07-21 | Bar-Ilan University | Interactive transparent individual cells biochip processor |
| IL154677A0 (en) | 2003-02-27 | 2003-09-17 | Univ Bar Ilan | A method and apparatus for manipulating an individual cell |
| US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
| US8597597B2 (en) | 2003-06-26 | 2013-12-03 | Seng Enterprises Ltd. | Picoliter well holding device and method of making the same |
| US20060240548A1 (en) * | 2003-06-26 | 2006-10-26 | Mordechai Deutsch | Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof |
| US7888110B2 (en) | 2003-06-26 | 2011-02-15 | Seng Enterprises Ltd. | Pico liter well holding device and method of making the same |
| WO2005008626A1 (en) * | 2003-07-11 | 2005-01-27 | University Of North Carolina At Chapel Hill | Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop |
| US20050064524A1 (en) * | 2003-08-11 | 2005-03-24 | Mordechai Deutsch | Population of cells utilizable for substance detection and methods and devices using same |
| EP1666059A4 (en) * | 2003-08-11 | 2008-08-27 | Univ Osaka Res Found | NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY |
| NZ603105A (en) * | 2003-10-23 | 2014-08-29 | Kineta Two Llc | Detection of mutations in a gene associated with resistance to viral infection, oasi |
| CN103495153A (zh) | 2003-10-23 | 2014-01-08 | 奇尼塔二有限责任公司 | 检测与抗病毒感染性有关的基因oas1中的突变的方法 |
| GB2426521A (en) | 2004-02-02 | 2006-11-29 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
| US7544805B2 (en) * | 2004-02-03 | 2009-06-09 | Chemagis Ltd. | Stable amorphous forms of montelukast sodium |
| CA2555412C (en) * | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
| CA2610632C (en) | 2004-06-01 | 2022-10-04 | Mount Sinai School Of Medicine Of New York University | Genetically engineered swine influenza virus and uses thereof |
| US20080063251A1 (en) * | 2004-07-07 | 2008-03-13 | Mordechai Deutsch | Method and Device for Identifying an Image of a Well in an Image of a Well-Bearing |
| US7403647B2 (en) * | 2004-09-13 | 2008-07-22 | Seng Enterprises Ltd. | Method for identifying an image of a well in an image of a well-bearing component |
| WO2009100255A2 (en) | 2008-02-08 | 2009-08-13 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| EP1781404A2 (en) * | 2004-08-25 | 2007-05-09 | Seng Enterprises Limited | Method and device for isolating cells |
| US20060051369A1 (en) * | 2004-08-27 | 2006-03-09 | Taylor Deborah R | ADAR1 antiviral pathway |
| US20080107683A1 (en) * | 2004-11-30 | 2008-05-08 | David Hone | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
| EP1866075B1 (en) | 2005-01-25 | 2010-09-08 | Seng Enterprises Limited | Microfluidic device for studying cells |
| US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
| ATE412737T1 (de) * | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| UA95446C2 (ru) | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
| DE102005034043B4 (de) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch |
| US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
| US20070141555A1 (en) * | 2005-10-11 | 2007-06-21 | Mordechai Deutsch | Current damper for the study of cells |
| US8288120B2 (en) | 2005-11-03 | 2012-10-16 | Seng Enterprises Ltd. | Method for studying floating, living cells |
| US20070196333A1 (en) * | 2006-02-23 | 2007-08-23 | Fu-Yung Lin | Composition comprising mixtures of IFN-alpha subtypes |
| US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
| JP2010525821A (ja) | 2007-05-02 | 2010-07-29 | アンブルックス，インコーポレイテッド | 修飾ＩＦＮβポリペプチドおよびこれらの使用 |
| US9145540B1 (en) | 2007-11-15 | 2015-09-29 | Seng Enterprises Ltd. | Device for the study of living cells |
| US9975118B2 (en) | 2007-11-15 | 2018-05-22 | Seng Enterprises Ltd. | Device for the study of living cells |
| EP2133358A1 (en) * | 2008-06-10 | 2009-12-16 | Universitätsklinikum Freiburg | Rift valley fever virus-like particles and their use for immunization and as test system |
| EP2318044B1 (en) | 2008-08-01 | 2015-12-02 | Gamma Vaccines Pty Limited | Influenza vaccines |
| BRPI0923448A2 (pt) | 2008-12-16 | 2018-10-09 | Baxter Int Inc E Baxter Healthcare S A | vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. |
| WO2011130119A2 (en) | 2010-04-14 | 2011-10-20 | Millipore Corporation | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| EP2667891B1 (en) | 2011-01-27 | 2021-10-06 | Gamma Vaccines Pty Limited | Combination vaccines |
| WO2013182498A1 (en) * | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| CN108588027A (zh) | 2013-02-05 | 2018-09-28 | 乔治亚大学研究基金公司 | 用于病毒生产的细胞系和使用方法 |
| KR20170122786A (ko) | 2015-02-26 | 2017-11-06 | 베링거잉겔하임베트메디카게엠베하 | 2가 돼지 인플루엔자 바이러스 백신 |
| WO2017070167A1 (en) * | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
| KR102651055B1 (ko) | 2016-03-24 | 2024-03-26 | 삼성디스플레이 주식회사 | 광학 필름 및 디스플레이 장치 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| JPS5754586A (en) * | 1980-09-18 | 1982-04-01 | Ajinomoto Co Inc | Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it |
| US4579821A (en) * | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| JPS58209993A (ja) * | 1982-05-31 | 1983-12-07 | Mochida Pharmaceut Co Ltd | インタ−フエロンの産生方法 |
| FI832252A7 (fi) * | 1982-06-21 | 1983-12-22 | The Wellcome Foundation Ltd | Parannettu menetelmä interferonin tuottamiseksi. |
| US4485038A (en) * | 1982-10-19 | 1984-11-27 | Health Research (Roswell Park Division) | Method for the production and purification of human leukocyte interferon |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4745053A (en) * | 1983-07-08 | 1988-05-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo | Process for producing human interferon and method for assaying the interferon productivity of blood |
| JPS6062997A (ja) * | 1983-09-17 | 1985-04-11 | Mochida Pharmaceut Co Ltd | インタ−フエロンの生産方法 |
| US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| DK0414475T3 (da) * | 1989-08-25 | 1998-02-09 | Chiron Corp | Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier |
| US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
| JPH05260981A (ja) * | 1992-03-02 | 1993-10-12 | Massachusetts Inst Of Technol <Mit> | ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ |
| FR2689520B1 (fr) * | 1992-04-03 | 1996-07-19 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques. |
| US5840565A (en) | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
-
1996
- 1996-08-21 US US08/700,198 patent/US5840565A/en not_active Expired - Lifetime
- 1996-08-22 JP JP51050897A patent/JP4267693B2/ja not_active Expired - Lifetime
- 1996-08-22 DE DE69634360T patent/DE69634360T2/de not_active Expired - Lifetime
- 1996-08-22 EP EP96929066A patent/EP0846160B1/en not_active Expired - Lifetime
- 1996-08-22 AU AU68576/96A patent/AU6857696A/en not_active Abandoned
- 1996-08-22 CA CA002229405A patent/CA2229405C/en not_active Expired - Fee Related
- 1996-08-22 AU AU68608/96A patent/AU707130B2/en not_active Expired
- 1996-08-22 WO PCT/US1996/013627 patent/WO1997008324A1/en not_active Ceased
- 1996-08-22 BR BR9610550A patent/BR9610550A/pt not_active Application Discontinuation
- 1996-08-22 JP JP51045097A patent/JP3432519B2/ja not_active Expired - Fee Related
- 1996-08-22 CN CNB961977515A patent/CN1161469C/zh not_active Expired - Fee Related
- 1996-08-22 AT AT96929066T patent/ATE289348T1/de active
- 1996-08-22 CA CA2229163A patent/CA2229163C/en not_active Expired - Lifetime
- 1996-08-22 EP EP96929017A patent/EP0846174A4/en not_active Withdrawn
- 1996-08-22 WO PCT/US1996/013745 patent/WO1997008292A1/en not_active Ceased
-
1999
- 1999-11-19 US US09/444,224 patent/US6159712A/en not_active Expired - Fee Related
-
2000
- 2000-06-12 US US09/591,813 patent/US6489144B1/en not_active Expired - Fee Related
- 2000-12-13 US US09/736,748 patent/US6673591B2/en not_active Expired - Fee Related
- 2000-12-13 US US09/737,126 patent/US6686190B2/en not_active Expired - Lifetime
-
2003
- 2003-11-24 US US10/722,349 patent/US7132271B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2229405A1 (en) | 1997-03-06 |
| AU6857696A (en) | 1997-03-19 |
| US20010001709A1 (en) | 2001-05-24 |
| US20040157310A1 (en) | 2004-08-12 |
| CN1161469C (zh) | 2004-08-11 |
| WO1997008292A1 (en) | 1997-03-06 |
| JP4267693B2 (ja) | 2009-05-27 |
| AU707130B2 (en) | 1999-07-01 |
| WO1997008324A1 (en) | 1997-03-06 |
| EP0846160A1 (en) | 1998-06-10 |
| ATE289348T1 (de) | 2005-03-15 |
| DE69634360T2 (de) | 2005-12-29 |
| US20010001290A1 (en) | 2001-05-17 |
| EP0846174A1 (en) | 1998-06-10 |
| MX9801423A (es) | 1998-05-31 |
| US6673591B2 (en) | 2004-01-06 |
| BR9610550A (pt) | 1999-07-06 |
| EP0846160B1 (en) | 2005-02-16 |
| US6686190B2 (en) | 2004-02-03 |
| EP0846160A4 (en) | 2002-01-02 |
| JP3432519B2 (ja) | 2003-08-04 |
| AU6860896A (en) | 1997-03-19 |
| US6159712A (en) | 2000-12-12 |
| JPH11514344A (ja) | 1999-12-07 |
| EP0846174A4 (en) | 2003-02-05 |
| US5840565A (en) | 1998-11-24 |
| CA2229163C (en) | 2011-04-05 |
| US7132271B2 (en) | 2006-11-07 |
| CN1200148A (zh) | 1998-11-25 |
| CA2229163A1 (en) | 1997-03-06 |
| US6489144B1 (en) | 2002-12-03 |
| DE69634360D1 (de) | 2005-03-24 |
| JPH11511324A (ja) | 1999-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2229405C (en) | Methods for enhancing the production of interferon in cell culture | |
| JP2515308B2 (ja) | ヒト免疫インタ−フエロン | |
| Pirhonen et al. | Virus infection activates IL-1β and IL-18 production in human macrophages by a caspase-1-dependent pathway | |
| JP3260368B2 (ja) | インターロイキン−１０による腫瘍性疾患の処置 | |
| JP2003509012A (ja) | 細胞培養物中でのサイトカインの産生を増強するための方法 | |
| US6864061B2 (en) | Method for screening compounds for anti-inflammatory activity | |
| EP1214399B1 (en) | High level cytokine production with enhanced cell viability | |
| US6855519B2 (en) | Methods for enhancing the production of interferon in cell culture | |
| US5686263A (en) | Method for enhancing gene expression | |
| MXPA98001423A (en) | Methods to improve the production of viral vaccines in cellular cultivation through interruption suppression | |
| Mosmann | Section II: In Vitro Effects of IL-4 121 | |
| JPH0832236B2 (ja) | 組換えヒトインターロイキン２およびその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |